

(B2)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 387 941
A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 90200526.3

(51) Int. Cl. 5: **C07D 413/04, A61K 31/415,**
C07D 417/04, C07D 403/04,
C07D 261/20, C07D 275/04,
C07D 275/06, C07D 231/56


(22) Date of filing: 07.03.90

(30) Priority: 15.03.89 US 324270

(71) Applicant: **JANSSEN PHARMACEUTICA N.V.**
Turnhoutseweg 30
B-2340 Beerse(BE)(43) Date of publication of application:
19.09.90 Bulletin 90/38(72) Inventor: **Raeymaekers, Alfons Herman**
Margaretha
Aanbeeldstraat 1
B-2340 Beerse(BE)
Inventor: Freyne, Eddy Jean Edgard
Jan van Eycklei 8
B-2638 Rumst(BE)
Inventor: Boeckx, Gustaaf Maria
Augustijnstraat 21
B-2360 Oud Turnhout(BE)(84) Designated Contracting States:
GR

(54) 5(6)-(benzisoxa-, benzisothia- or indazol-3-yl)-1H-Benzimidazol-2-yl carbamates.

(57) [5,(6)-(benzisoxa-, benzisothia- or indazol-3-yl)-1H-benzimidazol-2-yl]carbamates of formula



EP 0 387 941 A1

wherein R¹ is hydrogen, C₁-₄alkyl, halo, hydroxy or C₁-₄alkyloxy; R² is C₁-₄alkyl; and X is O, S, SO, SO₂ or NR³; said R³ being hydrogen, C₁-₄alkyl, aryl or arylC₁-₄alkyl. The compounds of formula (I) have anthelmintic properties. Compositions containing said compounds as active ingredient, a method of combating helminths, and a process for preparing said compounds and compositions.

EP 0 387 941 A1

[5(6)-(BENZISOXA-, BENZISOTIA- OR INDAZOL-3-YL)-1H-BENZIMIDAZOL-2-YL]CARBAMATESBackground of the invention

A large number of benzimidazole carbamates have been described as anthelmintics. As most successful representatives there may be named mebendazole and flubendazole both described in U.S. Pat. No. 3,657,267, albendazole described in U.S. Pat. No. 3,915,986, oxicabendazole described in U.S. Pat. No. 3,682,952 and fenbendazole described in U.S. Pat. No. 3,954,791.

The benzimidazole carbamates of the present invention differ therefrom by the fact that they contain a benzimidazole moiety which is invariably substituted in the 5(6) position with a benzisoxa-, benzisothia-, or indazol radical and in particular by their favourable anthelmintic spectrum.

10


Description of the invention

The present invention is concerned with novel benzimidazole carbamates of formula

15

20

25



the acid addition or metal substitution salts thereof and the stereochemically isomeric forms thereof, wherein

R¹ is hydrogen, C₁-C₄alkyl, halo, hydroxy or C₁-C₄alkyloxy;

R² is C₁-C₄alkyl; and

X is O, S, SO, SO₂ or NR³, said R³ being hydrogen, C₁-C₄alkyl, aryl or arylC₁-C₄alkyl; wherein aryl is phenyl optionally substituted with 1 or 2 substituents each independently selected from C₁-C₄alkyl, halo, hydroxy or C₁-C₄alkoxy.

As used in the foregoing definitions the term "halo" is generic to fluoro, chloro, bromo and iodo and the term "C₁-C₄alkyl" is meant to include straight and branch chained saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl, propyl, 1-methylethyl, 1,1-dimethylethyl, 2-methylpropyl, butyl and the like.

The compounds of formula (I) may occur in tautomeric forms which tautomeric forms are intended to be within the scope of the present invention.

Preferred compounds within the present invention are those compounds of formula (I) wherein R¹ is hydrogen or halo; R² is C₁-C₄alkyl; and X is O, S or NR³, said R³ being hydrogen, C₁-C₄alkyl or aryl.

Particularly preferred compounds within the present invention are those preferred compounds wherein R¹ is hydrogen or fluoro and/or R² is methyl or ethyl and/or X is O, S or NR³, wherein R³ is hydrogen, methyl or phenyl.

More preferred compounds within the invention are those preferred compounds wherein R¹ is hydrogen, R² is methyl and X is O or S.


The most preferred compounds of the invention are selected from the group consisting of methyl [5-(1,2-benzisoxazol-3-yl)-1H-benzimidazol-2-yl]carbamate and the pharmaceutically acceptable acid addition or metal substitution salts thereof.

The acid addition and metal substitution salts as mentioned hereinabove comprise the therapeutically active, and in particular, pharmaceutically acceptable non-toxic acid addition and metal substitution salt forms which the compounds of formula (I) are able to form. The acid addition salts can conveniently be obtained by treating the base form with appropriate acids such as, for example, inorganic acids, such as hydrochloric acid, e.g. hydrochloric, hydrobromic and the like, and sulfuric acid, nitric acid, phosphoric acid and the like; or organic acids such as, for example, acetic, hydroxyacetic, propanoic, 2-hydroxypropanoic,

EP 0 387 941 A1


2-oxopropanoic, ethanedioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-2-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. The metal substitution salts hereinabove are meant to comprise the 5 therapeutically active non-toxic metal substitution salt forms or metal complexes which the compounds of formula (I) are able to form, the term metal also comprising ammonium. The latter can conveniently be obtained by treating the compounds of formula (I) with appropriate inorganic bases or salts, for example, ammonia or bases derived from alkali or earth alkaline metals, e.g. alkali metal or earth alkaline metal oxides or hydroxides such as sodium hydroxide, calcium hydroxide, calcium oxide and the like. Conversely 10 the salt form can be converted by treatment with alkali into the free base form or with acid into the free acidic form. The term salt also comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

The compounds of formula (I) can generally be prepared by ring closure of an appropriately substituted 15 benzenediamine of formula (II) or an acid addition salt thereof, with an appropriate isourea or isothiourea derivative of formula (III).



In the formulae (II) and (III) the symbols X, R¹ and R² have the same meaning as described for formula (I) hereinbefore, whereas Y is S or O and R⁴ is hydrogen or a radical of formula -COOR².

Without being bound by any theory, it is assumed that the intermediates of formula (III) may occur in 30 tautomeric forms as tentatively illustrated in the following scheme.



Such tautomeric forms are naturally intended to be within the meaning of formula (III).

The cyclization of (II) with (III) can conveniently be carried out by stirring the reactants in a suitable 40 solvent preferably in the presence of an appropriate acid, either organic or inorganic. Organic acids comprise, for example, carboxylic acids, e.g. formic, acetic or propionic acid. Somewhat elevated temperatures may be appropriate to enhance the rate of the reaction and most preferably the reaction is carried out at the reflux temperature of the reaction mixture. In certain instances it may be advantageous to carry out 45 the reaction under pressure. Suitable solvents comprise organic solvents such as, for example, lower alkanols, e.g. methanol, ethanol, 2-propanol and the like alcohols; aromatic hydrocarbons, e.g. benzene, methylbenzene and the like; halogenated hydrocarbons, e.g. trichloromethane, dichloromethane, trichloroethane, trichloroethylene, chlorobenzene and the like; ethers such as tetrahydrofuran; ketones such as 50 2-propanone, 3-methyl-2-butanone; esters such as ethyl acetate; nitriles, e.g. acetonitrile and the like; and other common polar aprotic solvents such as, N,N-dimethylformamide, N,N-dimethylacetamide and the like solvents. Mixtures of such solvents with water may also be employed, e.g. mixtures of water with lower alkanols.

Benzimidazole carbamates of formula (I) may also be prepared by reacting a benzenediamine of formula (II) or an acid addition salt thereof with a cyanocarbamate of formula (IV).


55 (II) + NC-NH-COOR¹ (IV) → (I)

Said reaction may be effected according to art-known procedures as described, for example, in U.S. Pat. Nos. 3,682,952 and 3,969,526, by reacting a benzenediamine of formula (II) or an acid addition or metal substitution salt thereof with a cyanocarbamate of formula (IV) in a suitable solvent such as, for example,

EP 0 387 941 A1

water; a lower alkanol, e.g. methanol, ethanol; a ketone, e.g. 2-propanone; a polar aprotic solvent, e.g. N,N-dimethylformamide, N,N-dimethylacetamide, pyridine; or a mixture of such solvents, optionally in the presence of an acid such as, for example, a mineral acid, e.g. hydrochloric acid. Somewhat elevated temperatures may be appropriate to enhance the rate of the reaction, more in particular the reaction may be 5 conducted between 30 and 100 °C. In some instances it is appropriate to prepare the cyano carbamate of formula (IV) in situ by reacting an appropriate halo formate ester (V), e.g. chloroformate ester with an aqueous solution of cyanamide or its calcium salt in the presence of an appropriate base such as, for example, an alkali metal carbonate or hydroxide.

Alternatively, the benzimidazole carbamates of formula (I) may be prepared by reacting a benzenediamine of formula (II) with cyanogen bromide (VI) and reacting the thus obtained 2-aminobenzimidazole (VII) with an appropriate haloformate ester (V), e.g. chloroformate ester.



The benzimidazole carbamates of formula (I) may alternatively be prepared under similar procedures as are described in the literature for the preparation of related benzimidazole carbamates starting from appropriately substituted benzenediamines. A number of such procedures are described, for example, in "The chemistry of Heterocyclic Compounds" Vol. 40, part 1, pages 1-60, J. Wiley & Sons, New York (1981) and the references and Patents cited therein.

In all of the foregoing and in the following preparations, the reaction products may be isolated from the reaction mixture and, if necessary, further purified according to methodologies generally known in the art such as, for example, extractions, distillation, crystallization, trituration and chromatography.


30 The compounds of formula (I) may also be converted into each other following art-known functional group transformation procedures.

35 The compounds for formula (I), wherein X is S may be converted into the corresponding compounds of formula (I), wherein X is SO or SO₂ by an appropriate oxidation reaction, e.g. by reacting the former compounds with a suitable oxidizing agent such as, for example, sodium chlorate, potassium permanganate, potassium periodate, a peroxide, e.g. 3-chlorobenzenecarboperoxyic acid, hydrogen peroxide and the like in a suitable solvent such as, an ether, e.g. tetrahydrofuran, 1,1'-oxybisethane, a hydrocarbon, e.g. benzene, a halogenated hydrocarbon, e.g. dichloromethane and the like. In the instance where a sulfoxide is desired, said oxidation reaction is preferably conducted at lower temperatures with approximately one equivalent of the oxidizing agent, while were a sulfonyl is desired, said oxidation reaction may be conducted 40 at room or at an elevated temperature with an excess of oxidizing agent.


Some intermediates and starting materials in the foregoing preparations are known compounds which may be prepared according to art-known methodologies of preparing said or similar compounds and others are new. A number of such preparation methods will be described hereinafter in more detail.

45 The intermediates of formula (II) can be prepared from the corresponding nitro-substituted intermediates (VIII) following art-known nitro-to-amine reduction procedures such as for example, catalytic hydrogenation in a suitable solvent e.g. methanol or ethanol, in the presence of hydrogen and an appropriate catalyst e.g. platinum-on-charcoal, palladium-on-charcoal, Raney nickel, and the like. In some cases it may be useful to add an appropriate catalyst poison such as thiophene to the reaction mixture. Alternatively, said nitro group 50 may also be reduced to an amino group by reaction with a reducing agent such as, for example, sodium sulfide, sodium dithionite and the like. Said reaction can be carried out by stirring the reactants in a suitable solvent such as for example, water, an alcohol e.g. methanol, ethanol or a mixture of such solvents.

EP 0 387 941 A1




10 The intermediates of formula (VIII), wherein X is S, said compounds being represented by formula (VIII-a), can be prepared by reacting an appropriately substituted benzoyl of formula (IX) with sulfur and ammonia in a reaction-inert solvent such as, for example, an ether, e.g. 1,1'-oxybismethane, 2-methoxyethanol and the like, optionally under pressure.



25 In formula (IX) Z represents an appropriate leaving group, such as, for example, halo, e.g. fluoro or chloro; or a nitro group.

The intermediates of formula (VIII), wherein X is NR³-a, with R³-a being hydrogen or C₁-4alkyl, said intermediates being represented by formula (VIII-b), can be obtained by reacting the benzoyl intermediate (IX) with an appropriate hydrazine derivative R³-a-NH-NH₂ (X) or an acid addition salt thereof.




Said reaction can be carried out in a suitable reaction-inert solvent optionally in the presence of a suitable base. Suitable solvents are, for example, water, alkanols, e.g. methanol, ethanol, 1-butanol and the like. Appropriate bases preferably are amines such as N,N-diethylethanamine, 4-ethylmorpholine, pyridine and the like.

45 The benzoyl intermediates of formula (IX) can also be treated with hydroxylamine or an appropriate hydrazine derivative R³-b-NH-NH₂ (XI) or an acid addition salt thereof to form an intermediate of formula (XII) wherein X is O or NR³-b, said X being represented by X¹, with R³-b being aryl or arylC₁-4alkyl. Said reaction can be carried out with or without a suitable reaction-inert solvent and optionally in the presence of a base. Suitable solvents are, for example, water, alkanols, e.g. methanol, ethanol, 1-butanol and the like. Appropriate bases preferably are amines, such as N,N-diethylethanamine, 4-ethylmorpholine, pyridine and the like.


50 The thus prepared intermediates of formula (XII) can readily be cyclized to obtain intermediates of formula (VIII), wherein X is O or NR³-b with R³-b being aryl or arylC₁-4alkyl, said intermediates being represented by formula (VIII-c).

EP 0 387 941 A1



Said cyclization reaction may conveniently be conducted by treatment with an appropriate base, preferably in a suitable reaction-inert solvent such as, for example, water; hydrocarbons, e.g., benzene, dichloromethane and the like; lower alkanols, e.g. methanol, ethanol and the like; dipolar aprotic solvents, e.g. N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide and the like; or mixtures of said solvents. Appropriate bases are for example, hydroxides, alkoxides or hydrides, e.g. sodium hydroxide, sodium methoxide, sodium hydride and the like bases.


The intermediates of formula (IX) can be obtained by an aromatic nucleophilic substitution reaction of the halo group of intermediate (XIII).



- In the foregoing definitions the term halo is generic to fluoro, chloro, bromo and iodo. The nucleophilic substitution reaction can be carried out with ammonia in a reaction-inert solvent such as for example, a hydrocarbon, e.g. pentane, benzene; a halogenated hydrocarbon such as dichloromethane and the like; an alcohol, e.g. methanol, ethanol and the like; a dipolar aprotic solvent, e.g. N,N-dimethylformamide, N,N-dimethylacetamide, dimethyl sulfoxide and the like.

The intermediates of formula (XIII) can in turn be obtained by Friedel-Crafts acylation of a benzene of formula (XIV) with an acyl halide, a carboxylic acid or an anhydride of formula (XV). Said Friedel-Crafts reaction can be carried out by stirring the reaction mixture optionally in the presence of a reaction-inert solvent and in the presence of a catalyst such as, for example, a Lewis acid, e.g. ferric chloride, ferric bromide, aluminium trichloride and the like. Suitable solvents are, for example, hydrocarbons, e.g. pentane, hexane, nitrobenzene, dichloromethane, tetrachloromethane and the like.


The intermediates of formula (VIII) wherein X is O, said intermediates being represented by formula (VIII-d), may also be prepared by cyclizing an activated oxime derivative of formula (XVI), wherein T is an acyl residue and more particularly is (C_1 - 4 alkyl or aryl)carbonyl, e.g. propionyl and the like; (C_1 - 4 alkyl or aryl)oxycarbonyl, e.g. methoxycarbonyl and the like; (C_1 - 4 alkyl or aryl)sulfonyl, e.g. methanesulfonyl, benzenesulfonyl and the like; N-acylaminocarbonyl, e.g. trichloromethylcarbonylaminocarbonyl and the like.




Said cyclization reaction of the activated oxime derivative of formula (XVI) may conveniently be conducted by treatment with an appropriate base, preferably in a suitable reaction-inert solvent. In some

EP 0 387 941 A1


instances however, it may be advantageous not to add a base to the reaction mixture and to remove the acid liberated during the reaction by distillation. Alternatively, said cyclization may also be effected by heating the oxime derivative (XVI) in *vacuo* without a solvent. Appropriate bases are for example, alkali and earth alkaline metal carbonates, hydrogen carbonates and amines, e.g. sodium carbonate, potassium carbonate, sodium hydrogen carbonate, *N,N*-diethylethanamine, pyridine and the like bases. Suitable solvents for said cyclization are, for example, aromatic hydrocarbons, e.g. benzene, methylbenzene and the like; ethers, e.g. 1,1'-oxybisethane, tetrahydrofuran, 1,4-dioxane and the like; dipolar aprotic solvents, e.g. *N,N*-dimethylformamide, *N,N*-dimethylacetamide and the like; halogenated hydrocarbons, e.g. trichloromethane, tetrachloromethane and the like solvents.



²⁰ Preferably, the aniline (XVII) is treated with an alkali metal nitrite, e.g. sodium nitrite, in an aqueous acidic medium thus obtaining the corresponding N-nitroso compound (XVIII-a) or, in case R³ is hydrogen, thus obtaining the diazonium salt (XVIII-b).



³⁵ In formula (XVIII-a) R^{3-c} has the same meaning as R³ with the proviso that hydrogen is excluded and in formula (XVIII-b) A⁻ represents the conjugated base of the acid of the aqueous acidic medium mentioned hereinabove. The N-nitroso compound (XVIII-a) or the diazonium salt (XVIII-b) is treated with an appropriate reducing agent such as, for example, hydrogen in the presence of a hydrogenation metal catalyst, e.g. Raney nickel or Raney cobalt; or a sulfite, e.g. sodium sulfite; thus yielding the corresponding hydrazine derivative of formula (XIX), which in most instances spontaneously, or if necessary upon increasing the temperature, will cyclize to a compound of formula (II-a).




In the formulae (XVII), (XVIII) and (XIX) P represents a suitable protective group which preferably is readily removable by hydrogenation such as, phenylmethyl and the like. When using such protective group for the hydrogenation of (XVIII-a) or (XVIII-b), the unprotected intermediate (XIX) is obtained. In other instances, N-protected derivatives of formula (XIX) are obtained which may be deprotected, or may be converted as such to the N-protected intermediate (II-a), which is afterwards deprotected.

EP 0 387 941 A1

The isourea or isothiourea derivatives of formula (III) may be prepared by the reaction of an iso(thio)-urea of formula (XX) or an acid addition salt thereof with an appropriate haloformate ester (V), e.g. chloroformate ester, in the presence of a base, as illustrated in the following scheme; with Y and R⁴ being as defined hereinabove.

5



10

Suitable bases for the purpose of this procedure include metal alkoxides, metal hydroxides, alkali or earth alkali metal carbonates, hydrogen carbonates or organic bases, e.g. sodium methoxide, sodium hydroxide, sodium carbonate, sodium hydrogen carbonate, N,N-diethylethanamine and the like.

In some instances the compounds of formula (I) and some of the intermediates in this invention may have an asymmetric carbon atom in their structure, e.g. when R² is a branched alkyl. This chiral center may be present in a R- and a S-configuration, this R- and S-notation being in correspondence with the rules described in J. Org. Chem., 35, 2849-2867 (1970). These stereochemically isomeric forms of the compounds of formula (I) are naturally intended to be embraced within the scope of the invention.

Pure stereochemically isomeric forms of the compounds of this invention may be obtained by the application of art known procedures. Diastereoisomers may be separated by physical separation methods such as selective crystallization and chromatographic techniques, e.g. counter current distribution, and enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids, or the like methods.

Pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.

The compounds of formula (I), the pharmaceutically acceptable acid-addition salts and stereochemically isomeric forms thereof have anthelmintic properties, in particular they possess a broad spectrum activity against parasites of warm blooded animals (human or animal), including both mature and immature parasitic forms, as represented for example by Nematodes, such as, *Syngamus trachea* in turkeys and pheasants, *Ascaridia* and *Heterakis* in chickens, *Toxocara cati* in cats, *Ankylostoma tubaeforme* in cats, *Toxocara canis* in dogs, *Toxascaris leonina* in dogs, *Uncinaria stenocephala* in dogs, *Ankylostoma caninum* in dogs, *Trichuris vulpis* in dogs, *Trichinella spiralis* in pigs and rats, *Haemonchus contortus* in sheep, *Dictyocaulus filaria* in sheep and *Trichostrongylides* in sheep. Some compounds of the present invention are even found to be active against Cestodes, such as, *Taenia pisiformis* in dogs, *Taenia hydatigena* in dogs, *Taenia ovis* in dogs, *Dipylidium caninum* in dogs, *Taenia taeniaeformis* in cats, *Moniezia* in sheep, *Anitellina* sp in sheep, *Raillietina*, *Hydatigera taeniaeformis* and the like. In particular, the compounds of the invention are found to exhibit high activity against various helminths infecting the intestinal tract of man and economically important animals, such as, sheep, cattle, horses, pigs and poultry, coupled with low systemic toxicity to the host.

The anthelmintic properties of compounds of formula (I) can be demonstrated for example in the "*Taenia pisiformis* in artificially infected dogs"-test and the "*Heterakis gallinarium* in chicken"-test illustrating the useful anthelmintic properties of the compounds of the present invention.

In view of their useful anthelmintic properties the subject compounds may be formulated into various pharmaceutical forms for administration purposes. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually

EP 0 387 941 A1

comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like, may be employed. In the 5 compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a 10 spot-on, as a pour-on, as an ointment.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonsfuls, tablespoonsfuls and the like, and segregated multiples thereof.

In the instance where economically important animals are raised in large numbers, particularly poultry and birds, it is advantageous to add the compounds of formula (I) directly to the feed, as such or in the 20 form of a premix or concentrate. In addition, the compounds of formula (I) may also be administered dissolved or suspended in drinking water.

In view of the anthelmintic properties of the compounds of formula (I) it is evident that the present invention provides anthelmintic compositions comprising an anthelmintically effective amount of an active compound of formula (I), either alone or in admixture with other active therapeutic ingredients such as, 25 closantel, in admixture with suitable carriers.

In view of their potent activity in combating helminths the compounds of this invention constitute useful tools for the destroying or prevention of the growth of helminths and more particularly they can effectively be used in the treatment of subjects suffering from such helminths. Therefore the present invention provides a method of destroying or preventing the growth of helminths in warm blooded animals suffering 30 from such helminths by administration of an anthelmintically effective amount of a compound of formula (I), a pharmaceutically acceptable acid addition salt or a possible stereochemically isomeric form thereof.

Those of skill in treating warm blooded animals suffering from such parasites could easily determine the effective amount from the test results presented herein. In general it is contemplated that an effective amount would be from 1 to 100 mg/kg body weight, more particularly between 2.5 and 25 mg/kg body 35 weight, preferably in a single administration.

The following examples are intended to illustrate and not to limit the scope of the present invention. Unless otherwise stated all parts therein by weight.

40 Experimental Part

A. Preparation of the intermediates

45 Example 1

a) To a stirred mixture of 465 parts of 1,3-difluorobenzene and 133.3 parts of aluminum trichloride was added dropwise a mixture of 110.1 parts of 4-chloro-3-nitro-benzoyl chloride and 116 parts of aluminum 50 trichloride at 70 °C. After stirring for 2 hours at reflux temperature, the reaction mixture was poured into ice-water. There were added 127 parts of hydrochloric acid and the product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was stirred in 2,2'-oxybispropane. The product was filtered off and dried, yielding 130 parts (87.4%) of (4-chloro-3-nitrophenyl) (2,4-difluorophenyl)methanone; mp. 90.5 °C (interm. 1).

b) A mixture of 30 parts of intermediate 1 and 165 parts of dimethyl sulfoxide was stirred for 4 hours at room temperature and for 2 hours at 50 °C while ammonia was bubbled through. The reaction mixture was poured into 600 parts of ice-water. The precipitate was filtered off and crystallized from acetic acid. The product was filtered off, washed with 2,2'-oxybispropane and dried, yielding 23.3 parts (83.7%) of (4-amino-

EP 0 387 941 A1

3-nitrophenyl) (2,4-difluorophenyl)methanone (interm. 2).

c) A mixture of 23.3 parts of intermediate 2, 29.2 parts of hydroxylamine monohydrochloride and 196 parts of pyridine was stirred for 2 hours at reflux temperature. The reaction mixture was evaporated and the residue was stirred in 250 ml HCl 5%. The product was extracted with a mixture of trichloromethane and 5 methanol (9:1) The extract was dried, filtered and evaporated, yielding 24 parts (97.4%) of (E+Z) (4-amino-3-nitrophenyl) (2,4-difluorophenyl) methanone,oxime (interm. 3).

d) To a stirred mixture of 3.12 parts of a dispersion of sodium hydride in mineral oil (50%) and 47 parts of N,N-dimethylformamide was added dropwise a mixture of 24 parts of intermediate 3 and 94 parts of N,N-dimethylformamide at 25 °C (cooling on ice). The whole was stirred for 1 hour at room temperature and 10 was then poured into ice-water. After acidifying with hydrochloric acid, the solid was filtered off, washed with water and stirred in acetonitrile. The product was filtered off, washed with 2,2'-oxybispropane and dried, yielding 17.7 parts (79.0%) of 4-(6-fluoro-1,2-benzisoxazol-3-yl)-2-nitrobenzenamine; mp. 238.9 °C (interm. 4).

In a similar manner there were also prepared:
15 4-(1,2-benzisoxazol-3-yl)-2-nitrobenzenamine (interm. 5) and 2-nitro-4-(1-phenyl-1H-indazol-3-yl)-benzenamine (interm. 6).

Example 2

20 A mixture of 10.4 parts of (4-amino-3-nitrophenyl) (2-fluorophenyl)methanone, 14.03 parts of methylhydrazine and 79 parts of ethanol was stirred for 40 hours at reflux temperature. After cooling, the precipitated product was filtered off, washed with 2,2'-oxybispropane and dried, yielding 5.5 parts (51.3%) of 4-(1-methyl-1H-indazol-3-yl)-2-nitrobenzenamine; mp. 230.6 °C (interm. 7).

25 In a similar manner there was also prepared:
4-(1H-indazol-3-yl)-2-nitrobenzenamine (interm. 8).

Example 3

30 A mixture of 10.4 parts of (4-amino-3-nitrophenyl) (2-fluorophenyl)methanone, 1.3 parts of sulfur, 40 parts of ammonia and 194 parts of 2-methoxyethanol was stirred for 20 hours in an autoclave at 160 °C. The reaction mixture was evaporated and the residue was stirred in dichloromethane. The product was filtered off and dried, yielding 3.1 parts (28.6%) of 4-(1,2-benzisothiazol-3-yl)-2-nitrobenzenamine (interm. 35 9).

Example 4

40 A mixture of 7.65 parts of intermediate 5, 24.1 parts of sodium dithionite, 158 parts of ethanol and 100 parts of water was stirred for 2 hours at room temperature and for 1 1/4 hours at reflux temperature. The solvent was evaporated and to the residue there were added water and sodium carbonate. The product was extracted with a mixture of trichloromethane and methanol (90:10). The extract was dried, filtered and evaporated, yielding 4.6 parts (68.1%) of 4-(1,2-benzisoxazol-3-yl)-1,2-benzenediamine (interm. 10).

45 In a similar manner there were also prepared:
4-(6-fluoro-1,2-benzisoxazol-3-yl)-1,2-benzenediamine (interm. 11) and 4-(1,2-benzisothiazol-3-yl)-1,2-benzenediamine (interm. 12).

Example 5

50 A mixture of 4 parts of intermediate 6, 2 parts of a solution of thiophene in methanol 4%, 119 parts of methanol and 89 parts of tetrahydrofuran was hydrogenated at 50 °C and normal pressure with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was co-evaporated with methylbenzene, yielding 3.6 parts (99.9%) of 4-(1-phenyl-1H-indazol-3-yl)-1,2-benzenediamine (interm. 13).

In a similar manner there were also prepared:

4-(1-methyl-1H-indazol-3-yl)-1,2-benzenediamine (interm. 14) and 4-(1H-indazol-3-yl)-1,2-benzenediamine

EP 0 387 941 A1

(interm. 15).

B. Preparation of the final compounds

5


Example 6

A mixture of 4.5 parts of intermediate 10,6 parts of methyl (α -imino- α -methoxymethyl)-carbamate, 4.4 parts of acetic acid and 298 parts of trichloromethane was stirred and refluxed for 30 hours. The precipitated product was filtered off, washed successively with methanol, water, methanol and 2,2'-oxybispropane and dried, yielding 4.5 parts (73.0%) of methyl [5-(1,2-benzisoxazol-3-yl)-1H-benzimidazol-2-yl]-carbamate; mp. >300 °C (compound 1).

In a similar manner there were also prepared the compounds listed in Table 1.

15

Table 1



20

25

30

35

Comp.No.	X	R ¹	mp. (°C)
1	O	H	>300
2	O	6-F	>300
3	N-CH ₃	H	289.6
4	N-H	H	267.5
5	S	H	>300
6	N-C ₆ H ₅	H	decomp.

40

Elementary analysis data (carbon, hydrogen, nitrogen)

45

50

Comp. No.	C			H			N		
	Theor. value	Exp. value	Diff.		Theor. value	Exp. value		Exp. value	Diff.
1	62.34	62.19	-0.15	3.92	3.84	-0.08	18.17	18.25	+0.08
2	58.9	58.55	-0.35	3.40	3.32	-0.08	17.17	17.30	+0.13
3	63.54	63.00	-0.54	4.71	4.62	-0.09	21.79	21.57	-0.22
4	62.54	61.65	-0.89	4.26	4.20	-0.06	22.79	22.35	-0.44
5	59.25	58.22	-1.03	3.73	3.56	-0.17	17.27	16.91	-0.36
6	68.92	67.57	-1.35	4.47	4.34	-0.13	18.27	17.91	-0.36

55

C. Biological Examples

EP 0 387 941 A1

The strong anthelmintic activity of the compounds of formula (I) is clearly evidenced by the data obtained in the following experiments, which data are only given to illustrate the useful anthelmintic properties of all the compounds of formula (I) and not to limit the invention either with respect to the scope of susceptible parasites nor with respect to the scope of formula (I).

5

Example 7: *Taenia pisiformis* in artificially infected dogs

Proglottids of *Taenia pisiformis* were collected from the faecal material of the infected dogs. After 10 maceration and washing in tapewater the eggs were collected by passing the proglottids suspension through a sieve with aperture of 53 micron. The number of eggs was counted and about 1000 eggs were administered by gavage to young rabbits.

After 5 weeks the rabbits had infectious *Cysticercus pisiformis* in the peritoneal cavity. After autopsy of the rabbits the cysticerci were collected and administered orally in a gelatine capsule to young Beagle 15 dogs. The infective dose was about 15 cysticerci.

Two months after the artificial infection the dogs were moved to isolated cages on wire floor to confirm the tapeworms infection by faecal examination.

After a single treatment of these dogs with a compound of formula (I) the faecal material was collected every day for 4 days. Elimination of proglottids and scolices was recorded. Seven days after oral 20 administration of a compound of formula (I) the dogs were autopsied and the efficacy of the compound was determined on the basis of the presence (or absence) of scolices in the intestine.

For example, compound No. 1 showed 100% activity after a single treatment with 2.5 mg/kg.

25 Example 8: *Heterakis gallinarum* in chickens

A hybrid line of 4 weeks old male Hisex chickens were infected orally with 600 *Heterakis gallinae* eggs. The eggs were admixed in the normal chicken feed and administered for two consecutive days.

Five weeks after infection they were treated orally with the test compound in a gelatin capsule at 30 various dose levels. Each day after treatment and for 5 consecutive days the expelled nematodes were counted in the faeces. At the end of the experiment the animals were autopsied. The remaining nematodes were counted and identified. The percent efficacy is calculated, based on the ratio:

35

$$\frac{\text{number of expelled parasites} \times 100}{\text{number of expelled parasites} + \text{number of parasites at autopsy}}$$

For example, compound nos. 3 and 4 showed 100% after a single treatment 10 mg/kg.

40

D) Composition Examples

45 The following formulations exemplify typical pharmaceutical compositions in dosage unit form suitable for systemic or topical administration to warm-blooded animals in accordance with the present invention.

"Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I), a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof.

50

Example 9 : oral drops

55 500 g of the A.I. was dissolved in 0.5 l of 2-hydroxypropanoic acid and 1.5 l of the polyethylene glycol at 60≈80 °C. After cooling to 30≈40 °C there were added 35 l of polyethylene glycol and the mixture was stirred well. Then there was added a solution of 1750 g of sodium saccharin in 2.5 l of purified water and while stirring there were added 2.5 l of cocoa flavor and polyethylene glycol q.s. to a volume of 50 l, providing an oral drop solution comprising 10 mg of the A.I. (per ml). The resulting solution was filled into suitable containers.

EP 0 387 941 A1

Example 10 : oral solution

9 g of methyl 4-hydroxybenzoate and 1 part of propyl 4-hydroxybenzoate were dissolved in 4 l of boiling purified water. In 3 l of this solution were dissolved first 10 g of 2,3-dihydroxybutanedioic acid and thereafter 20 g of the A.I.: The latter solution was combined with the remaining part of the former solution and 12 l 1,2,3-propanetriol and 3 l of sorbitol 70% solution were added thereto. 40 g of sodium saccharin were dissolved in 0.5 l of water and 2 ml of raspberry and 2 ml of gooseberry essence were added. The latter solution was combined with the former, water was added q.s. to a volume of 20 l providing an oral solution comprising 5 mg of the A.I. per teaspoonful (5 ml). The resulting solution was filled in suitable containers.

Example 11 : capsules

20 g of the A.I., 6 g sodium lauryl sulfate, 56 g starch, 56 g lactose, 0.8 g colloidal silicon dioxide, and 1.2 g magnesium stearate were vigorously stirred together. The resulting mixture was subsequently filled into 1000 suitable hardened gelatin capsules, each comprising 20 mg of the A.I.

Example 12 : film-coated tabletsPreparation of tablet core

A mixture of 100 g of the A.I., 570 g lactose and 200 g starch was mixed well and thereafter humidified with a solution of 5 g sodium dodecyl sulfate and 10 g polyvinylpyrrolidone (Kollidon-K 90®) in about 200 ml of water. The wet powder mixture was sieved, dried and sieved again. Then there was added 100 g microcrystalline cellulose (Avicel®) and 15 g hydrogenated vegetable oil (Sterotex ®). The whole was mixed well and compressed into tablets, giving 10.000 tablets, each comprising 10 mg of the active ingredient.

30

Coating

To a solution of 10 g methyl cellulose (Methocel 60 HG®) in 75 ml of denatured ethanol there was added a solution of 5 g of ethyl cellulose (Ethocel 22 cps ®) in 150 ml of dichloromethane. Then there were added 75 ml of dichloromethane and 2.5 ml 1,2,3-propanetriol. 10 g of polyethylene glycol was molten and dissolved in 75 ml of dichloromethane. The latter solution was added to the former and then there were added 2.5 g of magnesium octadecanoate, 5 g of polyvinylpyrrolidone and 30 ml of concentrated colour suspension (Opaspray K-1-2109®) and the whole was homogenated. The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Example 13 : injectable solution

45 1.8 g methyl 4-hydroxybenzoate and 0.2 g propyl 4-hydroxybenzoate were dissolved in about 0.5 l of boiling water for injection. After cooling to about 50 °C there were added while stirring 4 g lactic acid, 0.05 g propylene glycol and 4 g of the A.I.. The solution was cooled to room temperature and supplemented with water for injection q.s. ad 1 l volume, giving a solution of 4 mg A.I. per ml. The solution was sterilized by filtration (U.S.P. XVII p. 811) and filled in sterile containers.

50

Example 14 : suppositories


55 3 g A.I. was dissolved in a solution of 3 g 2,3-dihydroxybutanedioic acid in 25 ml polyethylene glycol 400. 12 g surfactant (SPAN®) and triglycerides (Witepsol 555®) q.s. ad 300 g were molten together. The latter mixture was mixed well with the former solution. The thus obtained mixture was poured into moulds at a temperature of 37-38 °C to form 100 suppositories each containing 30 mg of the active ingredient.

EP 0 387 941 A1

Claims

1. A chemical compound of formula

5



10

15 an acid addition or a metal substitution salt thereof, or a stereochemically isomeric form thereof, wherein R¹ is hydrogen, C₁₋₄alkyl, halo, hydroxy or C₁₋₄alkyloxy; R² is C₁₋₄alkyl; and X is O, S, SO, SO₂ or NR³, said R³ being hydrogen, C₁₋₄alkyl, aryl or arylC₁₋₄alkyl; wherein aryl is phenyl optionally substituted with 1 or 2 substituents each independently selected from C₁₋₄alkyl, halo, hydroxy or C₁₋₄alkoxy.

20 2. A chemical compound according to claim 1 wherein R¹ is hydrogen or halo; R² is C₁₋₄alkyl; and X is O, S or NR³, said R³ being hydrogen, C₁₋₄alkyl or aryl.

25 3. A chemical compound according to claim 2 wherein R¹ is hydrogen or fluoro; R² is methyl or ethyl and X is O, S, NR³, said R³ being hydrogen, methyl or phenyl.

4. A chemical compound according to claim 3 wherein R¹ is hydrogen, R² is methyl and X is O or S.

5. A chemical compound according to claim 1 wherein the compound is methyl [5-(1,2-benzisoxazol-3-yl)-1H-benzimidazol-2-yl]carbamate.


6. An anthelmintic composition comprising a pharmaceutical carrier and as active ingredient an anthelmintic effective amount of at least one compound as claimed in any of claims 1-5.

30 7. A process for preparing a composition as claimed in claim 6 characterized in that the carrier is intimately mixed with the active ingredient.

8. A method of destroying or preventing the growth of helminths in warm-blooded animals suffering from such helminths by the administration of an anthelmintically effective amount of a compound as claimed in any of claims 1-5.

35 9. A chemical compound of formula

40




45

an acid addition salt thereof or a stereochemically isomeric form thereof, wherein R¹ is hydrogen, C₁₋₄alkyl, halo, hydroxy or C₁₋₄alkyloxy; and X is O, S, SO, SO₂ or NR³, said R³ being hydrogen, C₁₋₄alkyl, aryl or arylC₁₋₄alkyl; and aryl is phenyl optionally substituted with 1 or 2 substituents each independently selected from C₁₋₄alkyl, halo, hydroxy or C₁₋₄alkoxy.

50 10. A process for preparing a compound of formula

55


EP 0 387 941 A1



10

an acid addition or a metal substitution salt thereof, or a stereochemically isomeric form thereof, wherein
 R¹ is hydrogen, C₁-4alkyl, halo, hydroxy or C₁-4alkyloxy;
 R² is C₁-4alkyl; and
 X is O, S, SO, SO₂ or NR³, said R³ being hydrogen, C₁-4alkyl, aryl or aryLC₁-4alkyl;
 15 wherein aryl is phenyl optionally substituted with 1 or 2 substituents each independently selected from
 C₁-4alkyl, halo, hydroxy or C₁-4alkoxy,
characterized by
 a) cyclizing a benzenediamine of formula

20



25

30 wherein X is O, S or NR³ with R³ being hydrogen, C₁-4alkyl, aryl or aryLC₁-4alkyl, or an acid addition or
 metal substitution salt thereof, with an urea or isothiourea of formula

35




wherein Y is S or O and R⁴ is hydrogen or a radical of formula -COOR² with R² having the same meaning
 as defined hereinbefore, in a reaction-inert solvent;

40

b) reacting a benzenediamine of formula

45




50

or an acid addition salt thereof, with a cyanocarbamate of formula
 NC-NH-COOR¹ (IV)
 in a reaction-inert solvent;


55

c) reacting a benzenediamine of formula

EP 0 387 941 A1




10 with cyanogen bromide, and reacting the thus obtained 2-aminobenzimidazole of formula




with an haloformate ester of formula halo-COOR¹ (V) in a reaction-inert solvent, or optionally converting the compounds of formula (I) into each other following art-known functional group transformation procedures, and, if desired, converting the compounds of formula (I) into a therapeutically active non-toxic acid-addition 25 salt form by treatment with an appropriate acid or, conversely, converting the acid-addition or metal substitution salt into the free base form with alkali; and/or preparing stereochemically isomeric forms thereof.

11. A process for preparing a compound of formula (II) as defined in claim 9,
characterized by
30 a) reducing a nitrophenyl derivative of formula




b) cyclizing an intermediate of formula



thus obtaining an intermediate of formula (II) wherein X is NR³ and R³ is hydrogen, C₁-4alkyl, aryl or arylC₁-4alkyl, said intermediate being represented by formula

55

EP 0 387 941 A1



10 and optionally preparing salt forms or stereoisomers of the compounds of formula (II).

15

20

25

30

35

40

45

50

55



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 90 20 0526

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl.5)						
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim							
A	GB-A-1 070 702 (COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANIZATION) ---		C 07 D 413/04 A 61 K 31/415 C 07 D 417/04 C 07 D 403/04 C 07 D 261/20 C 07 D 275/04 C 07 D 275/06 C 07 D 231/56						
A	FR-A-1 423 609 (MERCK & CO., INC.) ---								
D,A	US-A-3 969 526 (R.J. GYURIK et al.) ---								
D,A	US-A-3 954 791 (H. LOEWE) ---								
D,A	US-A-3 657 267 (J.L.H. VAN GELDER) -----								
			TECHNICAL FIELDS SEARCHED (Int. Cl.5)						
			C 07 D 413/00 A 61 K 31/00 C 07 D 417/00 C 07 D 403/00 C 07 D 261/00 C 07 D 275/00 C 07 D 231/00						
<p>The present search report has been drawn up for all claims</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 33%;">Place of search</td> <td style="width: 33%;">Date of completion of the search</td> <td style="width: 34%;">Examiner</td> </tr> <tr> <td>THE HAGUE</td> <td>04-05-1990</td> <td>DE BUYSER I.A.F.</td> </tr> </table> <p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>				Place of search	Date of completion of the search	Examiner	THE HAGUE	04-05-1990	DE BUYSER I.A.F.
Place of search	Date of completion of the search	Examiner							
THE HAGUE	04-05-1990	DE BUYSER I.A.F.							